By Mardi Chapman via the Limbic, 2019
The use of combined xanthine oxidase inhibitors (febuxostat) with a uricosuric agent (lesinurad) has shown long term safety and efficacy in patients with tophaceous gout in a trial involving Australian centres.
In a two year follow up study, febuxostat and lesinurad were effective in lowering serum urate levels, reducing gout flares and decreasing the size and number of tophi, without comprising renal safety.
A 12-month extension of the CRYSTAL study, which first compared
combination therapy with febuxostat alone, has also confirmed there were no new adverse events in a second year of combination therapy.